The future of cancer research Prevention, screening, vaccines, and tumor-specific drug combos

被引:1
|
作者
Blanck, George [1 ,2 ]
机构
[1] Univ S Florida, Morsani Coll Med, Tampa, FL 33620 USA
[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Immunol Program, Tampa, FL 33612 USA
关键词
cancer and diet; cancer and inflammation; cancer prevention; cancer screening; cancer vaccines; carcinogens; designer drugs; tumor promoters; tumor-specific drugs; ACQUIRED-RESISTANCE; SOMATIC MUTATIONS; THERAPY; GENOME;
D O I
10.4161/hv.27458
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
New cancer research strategies have developed very rapidly over the past five years, including extensive DNA sequencing of tumor and normal cells; use of highly sensitive cancer cell detection methods; vaccine development and tumor-specific (designer) drugs. These developments have raised questions about where to concentrate efforts in the near future when establishing clinical trials, particularly important in an age of diminishing resources and during a period when competing strategies for cancer control are likely to overwhelm the opportunities for establishing large, effective clinical trials. In particular, it behooves the research community to be mindful of the inevitable, challenging obligation to responsibly choose between clinical trials that offer the credible hope of incremental advances vs. trials that are less traditional but may have revolutionary outcomes.
引用
收藏
页码:700 / 702
页数:3
相关论文
共 50 条
  • [41] Navigating cancer network attractors for tumor-specific therapy
    Creixell, Pau
    Schoof, Erwin M.
    Erler, Janine T.
    Linding, Rune
    NATURE BIOTECHNOLOGY, 2012, 30 (09) : 842 - 848
  • [42] MagForce® nanotherapy:: With tumor-specific nanoparticles against cancer
    Jordan, A
    NANOFAIR 2005: NEW IDEAS FOR INDUSTRY, 2005, 1920 : 111 - 116
  • [43] A Universal Tumor-Specific Promoter for Cancer Gene Therapy
    Alekseenko, I. V.
    Pleshkan, V. V.
    Sass, A. V.
    Filyukova, O. B.
    Snezhkov, E. V.
    Sverdlov, E. D.
    DOKLADY BIOCHEMISTRY AND BIOPHYSICS, 2018, 480 (01) : 158 - 161
  • [44] HPV vaccines and screening in the prevention of cervical cancer - Preface
    Bosch, F. Xavier
    VACCINE, 2006, 24 : V - VI
  • [45] Prevention of carcinoma development by tumor-specific Th1 cells
    Braumueller, Heidi
    Wieder, Thomas
    Bulotas, Gintautas
    Fischer, Sonja
    Roecken, Martin
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2010, 130 : S38 - S38
  • [46] SPECIFIC CANCER-THERAPY BY DRUGS ATTACHED TO TUMOR-SPECIFIC ANTIBODIES
    DAVIES, DAL
    ONEILL, GJ
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1976, 277 (SEP20) : 670 - 670
  • [47] TUMOR-SPECIFIC IDIOTYPE VACCINES .1. GENERATION AND CHARACTERIZATION OF INTERNAL IMAGE TUMOR-ANTIGEN
    RAYCHAUDHURI, S
    SAEKI, Y
    FUJI, H
    KOHLER, H
    JOURNAL OF IMMUNOLOGY, 1986, 137 (05): : 1743 - 1749
  • [48] Shared tumor antigens as vaccines for cancer prevention.
    Finn, OJ
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2002, 11 (10) : 1255S - 1255S
  • [49] Cancer vaccines compensate for the insufficient induction of protective tumor-specific immunity of CD3 bispecific antibody therapy
    Middelburg, Jim
    Schaap, Gaby
    Sluijter, Marjolein
    Lloyd, Katy
    Ovcinnikovs, Vitalijs
    Schuurman, Janine
    van der Burg, Sjoerd H.
    Kemper, Kristel
    van Hall, Thorbald
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (01)
  • [50] Comparing immunogenicities of tumor-specific antigens administered as therapeutic vaccines in metastatic melanoma patients
    Baurain, J.
    Stas, M.
    Neyns, B.
    Schuler, G.
    Velu, T.
    Thielemans, K.
    Van Baren, N.
    Dorval, T.
    Marchand, M.
    Coulie, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)